POTS / Dysautonomia
Autonomic nervous system dysfunction causing debilitating orthostatic symptoms. MSC therapy targets neuroinflammation and autonomic nerve repair.
Postural Orthostatic Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an excessive increase in heart rate upon standing, accompanied by debilitating symptoms including lightheadedness, fatigue, palpitations, brain fog, nausea, and pre-syncope. POTS affects an estimated 1–3 million Americans and disproportionately impacts women aged 15–50.
POTS is increasingly recognized as having autoimmune, small fiber neuropathy, and mast cell activation components — particularly in post-infectious cases. The surge in POTS diagnoses following COVID-19 has accelerated research into immune-mediated mechanisms of autonomic dysfunction. Standard therapy — beta-blockers, fludrocortisone, ivabradine, compression, and hydration — provides partial symptom relief but does not address the underlying pathology.
MSC therapy is being explored for POTS and dysautonomia as an approach to small fiber nerve repair, autonomic nerve regeneration, and immune-mediated autonomic dysfunction — targeting mechanisms that standard therapy cannot reach.
MSCs secrete neurotrophic factors — including NGF, GDNF, and BDNF — that directly promote small fiber nerve regeneration, the type most commonly damaged in POTS-associated small fiber neuropathy. In addition, MSC-mediated immune suppression targets autoantibodies against adrenergic and acetylcholine receptors that have been identified in subsets of POTS patients.
Anti-inflammatory MSC effects also address mast cell hyperactivation — a co-occurring condition in many POTS patients — by reducing degranulation through prostaglandin E2 and anti-inflammatory cytokine signaling. Vascular remodeling effects via VEGF secretion may also improve venous return and autonomic cardiovascular regulation.
True Regen evaluates POTS patients with tilt table testing, autonomic function assessment, small fiber nerve density biopsy reports, and autoantibody panels before designing a protocol. Post-treatment autonomic function and symptom scores are tracked at 3 and 6 months.
- Reduced heart rate increase on orthostatic challenge
- Improved cognitive clarity and reduced brain fog
- Decreased fatigue and exercise intolerance
- Reduced frequency of pre-syncopal episodes
- Improved small fiber nerve density on repeat biopsy
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.